Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 04, 2025 18:25 ET | Source: Foundation for Sarcoidosis Research

Foundation for Sarcoidosis Research Announces 2025 Global Virtual Sarcoidosis Summit – United for Progress: A New Chapter in Sarcoidosis

FSR Global Virtual Sarcoidosis Summit - June 28-29 - is the world’s largest online sarcoidosis event.
May 23, 2025 07:00 ET | Source: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s Disease

NEW YORK, May 23, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
May 19, 2025 12:06 ET | Source: Foundation for Sarcoidosis Research

The Coalition to Transform Clinical Trial Engagement Launches National “Champions for Change – PTO Initiative” to Expand Access to Clinical Trials for Working Patients with 7 Corporate and Non-Profit Members

Coalition to Transform Clinical Trial Engagement (CTCTE) announces launch of Champions for Change – Paid Time Off (PTO) Initiative.
May 15, 2025 08:00 ET | Source: Tiziana Life Sciences Ltd.

Journal of Clinical Nuclear Medicine Publishes Results of Tiziana’s Nasal Foralumab in Study Treating Moderate Alzheimer's Disease

NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
May 09, 2025 07:00 ET | Source: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab

NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
April 16, 2025 16:44 ET | Source: Biosidus

Biosidus Announces Promising Interim Results from Phase III Study on Agalsidase Beta for Fabry Disease

BUENOS AIRES, Argentina, April 16, 2025 (GLOBE NEWSWIRE) -- Biosidus, an Argentinean pioneer company in biotechnology research, development, and the production of high-quality biosimilars, has...
March 26, 2025 15:00 ET | Source: Custom Market Insights

[Latest] Global Fabry Disease Treatment Market Size/Share Worth USD 7.02 Billion by 2034 at a 9.8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

Austin, TX, USA, March 27, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Fabry Disease Treatment Market Size, Trends and Insights By Treatment (Enzyme...
February 27, 2025 11:51 ET | Source: D S Simon

UPDATE - YourUpdateTV Speaks with Alanna Morris-Simon from Bayer to Discuss Key Risk Factors for Heart Disease and Resources That Can Help

February is American Heart Month - Expert with Bayer Discusses Key Risk Factors for Heart Disease and Shares Practical Tips for Improving Heart Health NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- ...
February 24, 2025 10:34 ET | Source: D S Simon

YourUpdateTV Speaks with Alanna Morris-Simon from Bayer to Discuss Key Risk Factors for Heart Disease and Resources That Can Help

February is American Heart Month - Expert with Bayer Discusses Key Risk Factors for Heart Disease and Shares Practical Tips for Improving Heart Health NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) --...
February 11, 2025 09:15 ET | Source: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer’s Disease

NEW YORK, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...

Next Page keyboard_arrow_right